UK Mounjaro Price Rise Confirmed – What You Should Do Now

By Dr Mark Larkin PhD, Director, Pharmacy Price Hound

As I predicted in my blog on 8th August, Manufacturer Lilly formally confirmed on 12th August that its list price of Mounjaro (tirzepatide) will rise by up to 170% from £122 to £330 per month for the highest dose, effective 1st September, 2025—though NHS-supplied patients are unaffected.

This change reflects U.S. policy pressure—chief among them, the Trump administration’s push to eliminate differences in global drug prices by encouraging foreign price increases to facilitate U.S. price reductions. As such, UK private patients now face a significant hit to affordability.

What This Means for You:

• Sudden cost surge: Many private users are already paying more than double. Providers like Asda Online Doctor and MedExpress have noted spikes in demand—up to 350%—as patients rush to purchase at current rates.
• Strain on household budgets: For those covering treatment costs directly, this hike may force difficult choices—including debt, postponing treatment, or even considering unsafe alternatives.
• Possible shift to alternatives: Comparable treatments like Wegovy may now appear more cost-effective, driving a potential migration as affordability becomes paramount.

What You Should Do Immediately:

1. Compare current prices now via Pharmacy Price Hound—lock in existing rates while still available.
2. Secure future supply early—discuss with your prescriber and your pharmacy whether you can pre-order or bundle before the increase takes effect.
3. Sign up for free email price alerts  on our site—we’ll track price changes and notify you the moment rates begin to rise.
4. Consult your clinician—if the new price exceeds your budget, it’s wise to explore alternatives, or assess whether NHS access might be feasible for your situation.

This confirmed price surge underscores how quickly the pricing landscape for private medicines can shift—and why it’s smart to stay informed and proactive.